{
    "clinical_study": {
        "@rank": "94228", 
        "arm_group": {
            "arm_group_label": "Flutemetamol (18F)", 
            "description": "There are no interventions in this study. This study is to assess the images taken previously from another study, GE-067-007."
        }, 
        "biospec_descr": {
            "textblock": "Brain specimen retained. Subjects who had previously been dosed with Flutemetamol (18F)\n      Injection and imaged in Study GE067-007."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Data from subjects who had previously been dosed with Flutemetamol (18F) Injection and\n      imaged in Study GE-067-007, and who died on or before 10 June 2013, will be analyzed.  The\n      PET brain images previously obtained in Study GE-067-007 will be interpreted visually in\n      randomized by 5 independent readers who are blinded to all other subject information, and\n      the images will be classified as abnormal (positive for abnormal neuritic plaque density) or\n      normal (negative for abnormal neuritic plaque density).  The numbers of images in each\n      category will be used to calculate sensitivity and specificity."
        }, 
        "brief_title": "Re-Read Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Neuritic Plaque Density Determined Post-mortem", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cognitive Impairment.", 
        "condition_browse": {
            "mesh_term": [
                "Plaque, Amyloid", 
                "Cognition Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject was enrolled in prior Study GE067-007.\n\n          -  The subject died on or before 10 June 2013.\n\n          -  The subject's brain is judged to be of suitable quality for analysis, including all\n             regions necessary for analysis.\n\n        Exclusion Criteria:\n\n          -  Not Applicable"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "55 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Subjects who had previously been dosed with Flutemetamol (18F) Injection and imaged in\n        Study GE067-007."
            }
        }, 
        "enrollment": {
            "#text": "107", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02090855", 
            "org_study_id": "GE-067-026"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Princeton", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "08540"
                }, 
                "name": "GE Healthcare"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Re-Read Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Neuritic Plaque Density Determined Post-mortem", 
        "overall_official": {
            "affiliation": "GE Healthcare", 
            "last_name": "Paul Sherwin, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Finland: Finnish Medicines Agency", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Blinded visual assessment of each subject's Flutemetamol (18F) Injection brain PET images as positive or negative will be performed by 5 independent blinded readers trained in the interpretation of [18F]flutemetamol PET images through an electronic training program.", 
            "measure": "Blinded visual assessment of each subject's Flutemetamol (18F) Injection brain PET images", 
            "safety_issue": "No", 
            "time_frame": "Brain images will be assessed up to 1 year post subject's death."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02090855"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Sensitivity and specificity according to the recently published criteria by [Hyman et al. 2012].", 
            "measure": "Sensitivity and specificity according to the recently published criteria", 
            "safety_issue": "No", 
            "time_frame": "Brain images will be assessed up to 1 year post subject's death."
        }, 
        "source": "GE Healthcare", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Covance Laboratories Ltd.", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "H2O Clinical LLC", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "GE Healthcare", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}